Benralizumab (Systemic)

Brand names: Fasenra
Drug class: Antineoplastic Agents

Usage of Benralizumab (Systemic)

Asthma

Adjunctive maintenance therapy in patients ≥12 years of age with severe eosinophilic asthma.

Reduces asthma exacerbation rate, decreases oral corticosteroid dosage requirements, and improves FEV1 from baseline.

Not indicated for treatment of other eosinophilic conditions.

Not indicated for relief of acute bronchospasm or status asthmaticus.

Several clinical practice guidelines on asthma management are available, including the Global Initiative for Asthma (GINA) guidelines. In GINA, stepwise approach to treatment is recommended where specific drugs are added or adjusted up or down through a series of steps (1 through 5) to achieve symptom control while keeping the patient on the lowest effective treatment.

Biologic agents such as Benralizumab are generally recommended as add-on therapy for severe asthma.

Relate drugs

How to use Benralizumab (Systemic)

General

Pretreatment Screening

  • Screen for pre-existing parasitic helminth infections and treat infections prior to initiating benralizumab.

    • Patient Monitoring

  • Monitor for hypersensitivity reactions after administration of benralizumab. Discontinue benralizumab if hypersensitivity reactions occur.

    • Other General Considerations

  • Intended for use under guidance of a healthcare provider.
  • Do not abruptly discontinue systemic or inhaled corticosteroids (ICS) upon initiation of benralizumab therapy. Decrease corticosteroid dosages gradually, if appropriate, under the direct supervision of a prescriber.

    • Administration

    Sub-Q Administration

    Administer by sub-Q injection into the upper arm, thigh, or abdomen.

    Commercially available in prefilled syringes and autoinjectors. Prefilled syringe intended for administration by a clinician. Autoinjector pen may be administered by patient or caregiver after proper training provided and healthcare provider determines it is appropriate.

    Remove syringe or autoinjector from refrigerator and allow to sit at room temperature for about 30 minutes prior to injection; use within 24 hours or discard.

    Contains no preservatives; intended for single use only.

    Inject entire contents of prefilled syringe (1 mL providing 30 mg).

    Dosage

    Pediatric Patients

    Asthma Sub-Q

    Adolescents ≥12 years of age: Initially, 30 mg every 4 weeks for 3 doses followed by 30 mg every 8 weeks.

    Adults

    Asthma Sub-Q

    Initially, 30 mg every 4 weeks for 3 doses followed by 30 mg every 8 weeks.

    Prescribing Limits

    Special Populations

    Geriatric Patients

    The manufacturer makes no specific dosage recommendations for geriatric patients.

    Hepatic Impairment

    The manufacturer makes no specific dosage recommendations for patients with hepatic impairment.

    Renal Impairment

    The manufacturer makes no specific dosage recommendations for patients with renal impairment.

    Warnings

    Contraindications

  • History of hypersensitivity to benralizumab or any ingredient in the formulation.

    • Warnings/Precautions

    Sensitivity Reactions

    Hypersensitivity

    Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, rash) reported, generally occurring within hours or possibly days following administration. If hypersensitivity reaction occurs, discontinue benralizumab.

    Deterioration of Disease and Acute Episodes

    Not indicated for treatment of acute asthma symptoms or exacerbations, acute bronchospasm, or status asthmaticus.

    Reduction of Corticosteroid Dosage

    Do not abruptly discontinue systemic or inhaled corticosteroid therapy upon initiation of benralizumab therapy. If appropriate, reduce corticosteroid dosage gradually and supervise such reduction carefully.

    Parasitic Infection

    Immune response against some parasitic (helminth) infections may be altered. Not studied in patients with known parasitic infections. Treat patients with preexisting parasitic (helminth) infections before initiating benralizumab. If parasitic infection occurs and does not respond to anthelmintic treatment, interrupt benralizumab therapy until infection resolves.

    Immunogenicity

    Potential for immunogenicity. Development of anti-benralizumab antibodies detected in 13% of patients and associated with increased drug clearance and increased blood eosinophil concentrations; development of Neutralizing antibodies also detected. Evidence of an association between anti-benralizumab antibodies and efficacy or safety of the drug not observed.

    Specific Populations

    Pregnancy

    No evidence of fetal harm in monkeys following IV benralizumab during pregnancy. Potential effects of monoclonal antibodies (e.g., benralizumab) on the fetus more likely to occur in the third trimester.

    Registry information is available by calling 1-877-311-8972 or visiting [Web].

    Lactation

    Not known whether distributed into human milk. Since IgG distributes into milk in humans, benralizumab is expected to distribute into human milk.

    Consider benefits of breast-feeding and importance of drug to the woman; also consider potential adverse effects on the breast-fed child from the drug or underlying maternal condition.

    Pediatric Use

    Safety and efficacy not established in children <12 years of age.

    Evaluated in 62 adolescent patients 12–17 years of age with asthma; adverse effect profile generally similar to that observed in adults.

    Geriatric Use

    No overall differences in safety and efficacy in patients ≥65 years of age relative to younger adults, but increased sensitivity cannot be ruled out.

    Hepatic Impairment

    Pharmacokinetics not studied in patients with hepatic impairment.

    Renal Impairment

    Pharmacokinetics not studied in patients with renal impairment.

    Common Adverse Effects

    Common adverse effects (≥5%): headache, pharyngitis.

    What other drugs will affect Benralizumab (Systemic)

    No formal drug interaction studies to date.

    Drugs Metabolized by Hepatic Microsomal Enzymes

    CYP substrates: Pharmacokinetic interactions unlikely.

    Drugs Affected by Efflux Transport Systems

    Substrates of efflux transport systems: Pharmacokinetic interactions unlikely.

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords